Wielotorbielowatość nerek autosomalna recesywna: badanie fazy III leku OPC-41061
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)